Superbug News

The Superbug Stock Review. Deadly Antibiotic-Resistant Bacteria like ‘Candida Auris’ and Deadly and Virulent Viruses Like ‘CoronaVirus’ or ‘HIV’ which killed 32 million. If Wall Street’s Funded Biotechs Are Trying to Kill What Wants to Kill Us, We’ll Follow It.


Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially...

CoronaVirus Stocks in the News (Bloomberg, Benzinga).

INITIAL WATCHLIST Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40   Alpha Pro Tech, Ltd. (NYSE: APT) $6.00AstraZeneca plc (NYSE: AZN) $49BioCryst Pharmaceuticals, Inc.'s (NASDAQ: BCRX) $2.80  Cerus Corporation (NASDAQ: CERS)...
Citius Pharmaceutical, CTXR, Biotech Stock Review

Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below. Auris all over the room, even on the ceiling?.
AR THreats Report, Biotech Stock Reciew

AR Threats Report (CDC)

This report is dedicated to the 48,700 familieswho lose a loved one each year to antibiotic resistanceor Clostridioides difficile, and the...
Dyadic, Biotech Stock Review

Dyadic (DYAI) Highlights.

"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and...

Adding Citius (CTXR) $0.55 to Watch List.

Best Presentation at Dawson James Conference. We attended the Dawson James Conference on October 29th, which had over 20...
Dyadic, Biotech Stock Review

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.

Investor Presentation Slides From Dyadic (DYA) $6.40.

Really, How Do We Do It? Live Short Term Chart
candida auris, citius pharma, biotech stock review

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...

Latest article

Citius (CTXR) CEO Myron Holubiak Live on TV, 1:20 Today, June 30th.

VIDEO: Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
Citius Pharma

Citius Pharma (CTXR) On The Move.

One Of Our Top 5 Biotech Picks For 2020 Up 23% Yesterday, Indicating Up Another 24% This Morning. Inquiring Minds Want...
Biotech Stock Review

Meet The Billion-Dollar Family Company That Makes Purell (Forbes).

Jerry and Goldie Lippman cofounded Gojo in Akron, Ohio, in 1946. Forbes 3/20/2020 Panic buying is...